MDxHealth SA (NASDAQ:MDXH) Short Interest Up 129.3% in March
by Amy Steele · The Cerbat GemMDxHealth SA (NASDAQ:MDXH – Get Free Report) was the target of a large growth in short interest in March. As of March 13th, there was short interest totaling 39,057 shares, a growth of 129.3% from the February 26th total of 17,033 shares. Based on an average daily trading volume, of 99,293 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.1% of the company’s stock are sold short.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Intesa Sanpaolo Wealth Management acquired a new stake in MDxHealth during the fourth quarter worth about $36,000. GSA Capital Partners LLP acquired a new position in MDxHealth during the third quarter worth $48,000. Lido Advisors LLC purchased a new position in MDxHealth during the third quarter valued at $48,000. Squarepoint Ops LLC purchased a new position in MDxHealth during the fourth quarter valued at $51,000. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of MDxHealth in the third quarter valued at about $53,000.
MDxHealth Price Performance
MDxHealth stock traded down $0.26 during mid-day trading on Friday, reaching $2.44. 205,487 shares of the company traded hands, compared to its average volume of 158,206. The firm’s fifty day moving average is $3.44 and its two-hundred day moving average is $3.74. The company has a market capitalization of $120.78 million, a price-to-earnings ratio of -3.64 and a beta of 1.61. MDxHealth has a fifty-two week low of $1.36 and a fifty-two week high of $5.33.
MDxHealth (NASDAQ:MDXH – Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.04). MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. The company had revenue of $29.55 million for the quarter, compared to analysts’ expectations of $26.05 million. As a group, equities research analysts predict that MDxHealth will post -1.15 earnings per share for the current year.
Analyst Ratings Changes
A number of analysts have weighed in on the company. BTIG Research restated a “buy” rating and set a $7.00 target price on shares of MDxHealth in a report on Tuesday, December 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a research report on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $7.75.
Get Our Latest Stock Analysis on MDxHealth
About MDxHealth
MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.
MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.